147,294 members

Skip to content. | Skip to navigation

News

Final draft guidance recommends osteoporosis treatment as a new option for women at increased risk of fractures

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Final draft guidance recommends osteoporosis treatment as a new option for women at increased risk of fractures

Draft guidance published by NICE

Postmenopausal women who are at increased risk of osteoporotic fractures should be treated with denosumab if treatment with the currently available oral bisphosphonates alendronate, and either risedronate or etidronate is unsuitable, according to draft guidance published by NICE.

Denosumab (Prolia, Amgen) is licensed to treat postmenopausal women at increased risk of osteoporotic fractures. It is given by injection twice a year and works by reducing bone breakdown and increasing bone mass and strength. More …